Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 723
Rating:

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Prof Paul Richardson speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results of the ICARIA trial.

The phase III trial used isatuximab, pomalidomide and low-dose dexamethasone vs pomalidomide and low-dose dexamethasone to treat relapsed and refractory multiple myeloma.

Prof Richardson explains that the trial found an improvement in PFS and response rate from the three drug combination, as well as a manageable side effect profile.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation